Summit Therapeutics’ stock tumbles again as FDA recommends new trial for lung-cancer drug
The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.
<p>The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.</p>